Error processing SSI file
Error processing SSI file

Weekly Report: Influenza Summary Update

Week ending April 30, 2005-Week 17

Error processing SSI file

The following information may be quoted:

Synopsis:

Influenza activity in the United States peaked in early February and continued to decline during week 17 (April 24-30, 2005)*. Forty-two (3.6%) specimens tested by U.S. World Health Organization (WHO) and National Respiratory and Enteric Virus Surveillance System (NREVSS) collaborating laboratories were positive for influenza viruses. The proportion of patient visits to sentinel providers for influenza-like illness (ILI) was below the national baseline. The proportion of deaths attributed to pneumonia and influenza was below the epidemic threshold. There have been 31 influenza-associated pediatric deaths reported to CDC this season. For week 17, there were no reports of widespread influenza activity. One state reported regional influenza activity, 2 states reported local activity, and 32 states and New York City reported sporadic activity. Thirteen states and the District of Columbia reported no influenza activity.

Laboratory Surveillance*:

During week 17, WHO and NREVSS laboratories in the United States reported testing 1,176 specimens for influenza viruses, of which 42 (3.6%) were positive. Of these, 9 were influenza A(H3N2) viruses, 9 were influenza A viruses that were not subtyped, and 24 were influenza B viruses.

Since October 3, WHO and NREVSS laboratories in the United States have tested a total of 140,682 specimens for influenza viruses and 22,074 (15.7%) were positive. Among the 22,074 influenza viruses, 16,887 (76.5%) were influenza A viruses and 5,187 (23.5%) were influenza B viruses. Five thousand five hundred fifty-four (32.9%) of the 16,887 influenza A viruses have been subtyped: 5,538 (99.7%) were influenza A(H3N2) and 16 (0.3%) were influenza A(H1) viruses. The percentage of specimens testing positive for influenza during the last 3 weeks (weeks 15-17) has ranged from 1.2% in the West South Central region to 6.2% in the Mountain region**. Nationally, influenza B viruses became more frequently reported than influenza A viruses during the week ending March 26 and have predominated each week since then.

View Chart Data

Antigenic Characterization:

CDC has antigenically characterized 802 influenza viruses collected by U.S. laboratories since October 1, 2004: 6 influenza A(H1) viruses, 540 influenza A(H3N2) viruses, and 256 influenza B viruses. The hemagglutinin proteins of the influenza A(H1) viruses were similar antigenically to the hemagglutinin of the vaccine strain A/New Caledonia/20/99. One hundred fifty-four (29%) of the 540 influenza A(H3N2) isolates were characterized as antigenically similar to A/Wyoming/3/2003, which is the A/Fujian/411/2002-like (H3N2) component of the 2004-05 influenza vaccine, and 386 (71%) were characterized as A/California/7/2004-like. One hundred seventy-four of the influenza B viruses isolated this season belong to the B/Yamagata lineage and were characterized as B/Shanghai/361/2002-like, which is the influenza B component recommended for the 2004-05 influenza vaccine, and 28 showed somewhat reduced titers to ferret antisera produced against B/Shanghai/361/2002. Fifty-four influenza B viruses belong to the B/Victoria lineage.

Influenza B viruses currently circulating can be divided into two antigenically and genetically distinct lineages represented by B/Yamagata/16/88 and B/Victoria/2/87 viruses. B/Yamagata lineage viruses circulated widely between 1990 and 2001, during which time B/Victoria-like viruses were not identified outside of Asia. However, between March 2001 and October 2003, B/Victoria-like viruses predominated in many countries, including the United States, and the vaccine strains were changed accordingly. While both Victoria lineage and Yamagata lineage viruses have been reported worldwide during the past year, Yamagata lineage viruses have once again become predominant.

Pneumonia and Influenza (P&I) Mortality Surveillance*:

During week 17, 7.2% of all deaths reported by the vital statistics offices of 122 U.S. cities were attributed to pneumonia or influenza. This percentage is below the epidemic threshold of 7.7% for week 17.

View Full Screen

Influenza-Associated Pediatric Mortality*:

During week 17, one pediatric death was reported to CDC. For the entire season, 31 pediatric deaths have been reported to CDC from 13 states (California, Colorado, Florida, Georgia, Iowa, Maine, Massachusetts, Mississippi, New Jersey, New York, Ohio, Pennsylvania, and Vermont); all deaths were reported during January-April.

Influenza-Associated Pediatric Hospitalizations:

Laboratory-confirmed influenza-associated pediatric hospitalizations are monitored in two population-based surveillance networks^{?/sup>: the Emerging Infections Program (EIP) and the New Vaccine Surveillance Network (NVSN). During October 3, 2004–April 16, 2005, the preliminary influenza-associated hospitalization rate for children 0? years old reported by NVSN and EIP was 7.1 and 2.5 per 10,000, respectively. EIP also monitors hospitalizations in children aged 5-17 years, and the preliminary influenza-associated hospitalization rate for this age group was 0.4 per 10,000. The overall hospitalization rate reported by EIP for children aged 0-17 years was 1.1 per 10,000. In years 2000?004, the end-of-season hospitalization rate for NVSN ranged from 3.7 (2002-03) to 12 (2003-04) per 10,000 children. The 2003-04 end of season hospitalization rate for EIP was 7.8 per 10,000 children aged 0-4 years and 0.8 per 10,000 for children aged 5-17 years. The difference in rates between NVSN and EIP may be due to different case-finding methods and the different populations monitored. For a summary of the methods used in each system, please refer to the surveillance methods in the Flu Activity section of the CDC influenza website.}

View Full Screen

View Full Screen

Influenza-like Illness Surveillance*:

During week 17, 1.2%^†† of patient visits to U.S. sentinel providers were due to ILI. This percentage is below the national baseline of 2.5%. Regional percentages ranged from 0.1% in the West North Central region to 2.2% in the Pacific region. Due to wide variability in regional level data, it is not appropriate to apply the national baseline to regional level data.

View Chart Data | View Full Screen

Influenza Activity as Assessed by State and Territorial Epidemiologists*:

There were no reports of widespread influenza activity during week 17. New York reported regional influenza activity. Hawaii and New Jersey reported local activity. Thirty-two states (Alaska, Arizona, California, Colorado, Connecticut, Florida, Indiana, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Mexico, North Dakota, Ohio, Oregon, Pennsylvania, South Carolina, South Dakota, Tennessee, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin) and New York City reported sporadic activity. Thirteen states (Alabama, Arkansas, Georgia, Idaho, Illinois, Iowa, Mississippi, New Hampshire, North Carolina, Oklahoma, Rhode Island, Texas, and Wyoming) and the District of Columbia reported no influenza activity. Delaware and Montana did not report.

View Full Screen

--------------------------------------------------------------------------------

Foot notes

Report prepared: May 5, 2005

Error processing SSI file